-
NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology
•
China-based natural killer (NK) cell therapy developer NK CellTech has entered into a strategic partnership with 3SBio Inc. (HKG: 1530), a compatriot firm, to focus on advancing NK cell therapy technology. This collaboration aims to leverage the complementary technologies and resources of both companies, accelerating the research, development, and commercialization…
-
NK CellTech’s NK-Cell Therapy Gets Green Light from China’s NMPA for Solid Tumor Treatment
•
NK CellTech, a Shanghai-based developer of natural killer (NK) cell therapies, has announced that it has received clinical clearance from China’s National Medical Products Administration (NMPA) for its proprietary genetically modified NK-cell therapy. This marks a significant milestone as the company’s molecule is set to be assessed as a treatment…
-
Shanghai-Based NK CellTech Earns FDA IND Clearance for Non-Genetically Modified NK Cell Therapy
•
NK CellTech, a Shanghai-based developer of NK cell therapies, has announced that it has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) for its proprietary non-genetically modified natural killer cell therapy, NK010, for the treatment of ovarian cancer. This milestone marks NK CellTech as…
-
NK Celltech and RongCan Biotech Partner to Advance mRNA NK Cell Therapy and LNP Delivery System
•
Shanghai-based NK Celltech and RongCan Biotech have entered into a partnership agreement to establish a long-term collaboration in the field of LNP delivery systems, aiming to bolster the clinical application of mRNA on NK cell therapy. The financial details of the agreement have not been disclosed. Complementary Expertise and PlatformsNK…
